HST Global Announces Strategic Partner for Panamanian Facility Also Desires to Open Facility in Costa Rica

HAMPTON, Va.--()--HST Global, Inc. (OTCBB: HSTC) today announced that the global partner previously identified for the possible development of a Clinical Treatment Facility in Panama has also expressed a desire to open a Clinical Treatment Facility in Costa Rica.

HST Global is partnering with Greg Benson, President and CEO of Health Matters International, a Canadian Company. Greg and his company bring immense international knowledge in the Healthcare industry inside and outside the United States, specifically with influence in Central and South America. With Greg’s assistance, the Company intends to License the “FIT” protocol, as well as other pending protocols, to Clinical Treatment Facilities in both Panama and Costa Rica.

Greg Benson, President and CEO of Health Matters International, stated, “Ron and his team at HST Global are dedicated to bringing humanity alternative treatments for life threatening illnesses, specifically late stage cancer. HST Global is relying on international markets to gain a universal “footprint” and reach a worldwide audience. During communications with HST, it became apparent there were synergies between our companies that could be employed to develop Clinical Treatment Facilities in both Panama and Costa Rica.”

Mr. Ron Howell, CEO and President of HST Global, Inc., stated, “Greg and his team are familiar with the demographic peculiarities, economic conditions and political climate of Panama and Costa Rica. Through this strategic partnership, we will be able to utilize his knowledge as well as leverage and align our resources in an effort to develop our Panamanian and Costa Rican Treatment Facilities.”

About HST Global, Inc.

HST Global, Inc. is an Integrated Biotechnology Health and Wellness company that is developing and or acquiring a network of Wellness Centers worldwide that are primarily focused on the immunotherapy and alternative treatment of late stage cancer. In addition, the company intends to acquire innovative products for the treatment of late stage cancer. In this regard, the company primarily focuses on immunotherapy and alternative product candidates that are undergoing or have already completed significant clinical testing for the treatment of late stage cancer.

HST Global, Inc. wishes to inform readers that forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials by others; possible acquisitions of other technologies, assets or businesses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.

Contacts

HST Global, Inc.
Investor Relations
David Nesbitt, 757-766-6100
ir@hstglobal.com
www.hstglobal.com

Contacts

HST Global, Inc.
Investor Relations
David Nesbitt, 757-766-6100
ir@hstglobal.com
www.hstglobal.com